Elanco Animal Health (NYSE:ELAN) to Present at 43rd Annual J.P. Morgan Healthcare Conference – Exhibit Filed

Elanco Animal Health Incorporated recently announced that it will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The company is set to participate in this conference, which is a significant event in the healthcare industry. A copy of the presentation to be shared at the conference has been included as Exhibit 99.1 in the latest 8-K filing.

The presentation for the J.P. Morgan Healthcare Conference focuses on forward-looking statements regarding the company’s expected 2024 full-year and fourth-quarter results, 2025 outlook, and long-term expectations. Elanco Animal Health’s statements include insights on business strategies, growth plans, product development, and financial projections.

It is vital to note that the information shared in the presentation, as well as Exhibit 99.1, is provided for informational purposes and should not be considered as “filed” under the Securities Exchange Act of 1934. These materials are not to be incorporated by reference into any registration statements or other official documents without explicit mention in the filing.

In addition to participating in the J.P. Morgan Healthcare Conference, Elanco Animal Health has been focusing on driving revenue growth through innovation. The company highlighted six potential blockbusters that are expected to contribute to mid-single-digit organic constant currency growth in 2025. These potential blockbusters include products like Credelio Quattro, Zenrelia, AdTab, and others that are part of their diverse portfolio.

Elanco Animal Health showcased a strategic trajectory poised for sustainable revenue growth through market leadership in farm animal and pet health segments. The company’s focus on delivering high-impact innovation, sustainable revenue growth, margin expansion, and market share gains signals its commitment to value creation for shareholders.

Moreover, Elanco Animal Health’s financial performance in 2024 demonstrated strength and discipline in managing its debt profile and capital allocation. The company’s efforts have led to an improved debt profile, driving toward a reduction in the adjusted net leverage ratio.

As Elanco Animal Health moves forward, it aims to capitalize on the launch of innovative products, strengthen its market position, and continue its drive for sustainable growth and value creation.

The company’s leadership will be looking to leverage its diverse portfolio, innovation pipeline, and market expansion strategies to secure its position as a key player in the animal health industry in the years to come.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Elanco Animal Health’s 8K filing here.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.